SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-030026
Filing Date
2021-02-05
Accepted
2021-02-05 09:12:31
Documents
15
Period of Report
2021-02-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d122203d8k.htm   iXBRL 8-K 33242
2 EX-10.1 d122203dex101.htm EX-10.1 73683
3 EX-99.1 d122203dex991.htm EX-99.1 8255
7 GRAPHIC g122203g0205110305545.jpg GRAPHIC 3980
  Complete submission text file 0001193125-21-030026.txt   275642

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ziop-20210204.xsd EX-101.SCH 3089
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ziop-20210204_lab.xml EX-101.LAB 18906
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ziop-20210204_pre.xml EX-101.PRE 11875
8 EXTRACTED XBRL INSTANCE DOCUMENT d122203d8k_htm.xml XML 3539
Mailing Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129
Business Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129 617-259-1970
ZIOPHARM ONCOLOGY INC (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 21594024
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences